Canada
· Delayed Price · Currency is CAD Biomind Labs Company Description
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions.
The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of morbid obesity; and BMDO9 is in Phase I clinical trial for treatment of Parkinson’s disease.
It is also developing preclinical drug candidates, including BMND02 for the treatment of fibromyalgia, BMND03 for the treatment of addictive disorders, BMND05 for the treatment of chronic pain, BMND05 for the treatment of inflammatory disorders, and BMND07 for the treatment of major depressive disorder.
The company is headquartered in Canelones, Uruguay.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Alejandro Antalich |
Contact Details
Address: Building Ceibo Of. 002 Canelones, Ontario Ontario Uruguay | |
| Website | biomindlabs.com |
Stock Details
| Ticker Symbol | BMND |
| Exchange | Cboe Canada |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA0907021012 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Alejandro Antalich | Chief Executive Officer and Director |
| Oscar Alejandro León Bentancor CPA | Chief Financial Officer and Director |
| Paola Diaz Dellavalle Ph.D. | Chief Scientific Officer |
| Juan Presa | Chief Legal Officer |
| Martin Daners | Head of Quality Assurance and Regulatory Affairs |